Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: ING-1, XOMA.

Lionel D Lewis1

  • 1Section of Clinical Pharmacology, Dartmouth Hitchcock Medical Center and Dartmouth Medical School, Lebanon, NH 03756, USA. Lionel.D.Lewis@Dartmouth.edu

Current Opinion in Molecular Therapeutics
|September 30, 2003
PubMed
Summary
This summary is machine-generated.

XOMA is developing ING-1, a human engineered immunoglobulin G1 antibody, for treating carcinoma and solid tumors. Clinical trials began in 2000, with Phase I/II trials initiated by February 2002.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer.

Clinical and translational science·2025
Same author

Association of DPYD rs4294451, plasma uracil concentration, and sex with 5-fluorouracil exposure in patients with gastrointestinal cancer.

Cancer chemotherapy and pharmacology·2025
Same author

Clinical pharmacology in space for astronauts and earthlings.

British journal of clinical pharmacology·2025
Same author

Space travel-associated motion sickness and its treatment.

British journal of clinical pharmacology·2025
Same author

Phase II trial of blood-brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma.

Neuro-oncology advances·2024
Same author

Characterization of Stealth Liposome-Based Nanoparticles Encapsulating the ACAT1/SOAT1 Inhibitor F26: Efficacy and Toxicity Studies In Vitro and in Wild-Type Mice.

International journal of molecular sciences·2024
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • ING-1 is a human engineered immunoglobulin G1 antibody.
  • It is being developed as a potential therapeutic agent for various cancers.

Purpose of the Study:

  • To evaluate the safety and efficacy of ING-1 in patients with carcinoma and solid tumors.

Main Methods:

  • Phase I clinical trials initiated in November 2000 in the US.
  • Phase I/II clinical trials initiated by February 2002.

Main Results:

  • Data on safety and preliminary efficacy from ongoing trials.

Conclusions:

  • ING-1 shows potential as a novel treatment for solid tumors and carcinomas.
  • Further clinical investigation is warranted to establish its therapeutic value.